Q3 2026 Coherus Oncology, Inc. Earnings Conference Call - COHERUS ONCOLOGY INC

Explicit Guidance:

• Revenue (Loctrosis): Revising full-year 2026 net sales guidance to $54–57 million; expecting to achieve $15 million in quarterly revenue in Q4 2026; long-term goal to reach peak market share by 2028.
• Operating Expenses: Full-year 2026 combined OPEX expected between $170–175 million.
• Cost Reductions: Implementation of 30% headcount reduction (from ~140 to 100 FTEs) effective immediately (Q3 2026) to yield $6–7 million per quarter in recurring cost savings.
• Cash Burn Management: Targeting a reduction in quarterly revenue required to cover core burn from $30–35 million down to $25–30 million starting in 2027.
• Earnings Milestones: Potential for first earn-out milestone payment of $37.5 million based on Q3 2026 revenue reports from the Udenica divestiture; second milestone report due after Q1 2027.
• Cash Runway: Current runway estimated at less than 12 months from the 10-Q filing date without cost reductions, new funding, or milestone payments.

Business-Segment Outlook:

• Coherence Oncology Pipeline (TAGMO-Keto/Tegmo Ketox): Shifting strategic focus exclusively to esophageal cancer (both squamous cell and adenocarcinoma) for first and second lines.
  • Second-Line: Proceeding with a randomized study against chemotherapy to support accelerated approval; aiming for FDA Type B meetings in early 2027 to finalize dose (Project Optimus) and study design.
  • First-Line: Continued development expected post-second-line data or in parallel; aiming to address PD-L1 positive and negative populations.
  • Other Assets: Kesdoza-Keto (HCC) remains active with maturing data; no deprioritization announced, with expectations for additional insights in Q1 2027.
  • Future Combinations: Initiating TAGMO-Keto trials in combination with T-cell engagers (specifically referencing Tesiridamab/Pentidermab context) and Pasireotide.
• Commercial (Loctrosis):
  • Market Share: Currently 20–22% of the NPC market; target to displace 30% of patients currently on chemo-only and 40% on off-label IOs.
  • Expansion: Focus on converting chemo-only patients and off-label IO users via payer preference partnerships and clinical organization collaborations.
  • Geography: Pursuing ex-U.S. partnering discussions for TAGMO-Keto, specifically targeting high-incidence regions (e.g., Asia) to fund registration trials.

Market and Competitive Outlook:

• Competitive Positioning: Aiming to become the "best-in-disease" therapy for esophageal cancer by offering a chemo-free option in the second-line setting and superior durability in the first-line compared to current PD-1/chemo standards limited to PD-L1+ patients.
• Pricing/Payer: Expanding payer partnerships to establish preferential access for Loctrosis, currently achieving double the national average share of addressable patients in regions with active agreements.
• Market Dynamics: Expecting continued volatility ("lumpiness") due to rare disease patient flow; mitigating via claims-based alerts to identify under-treated patients and top-down initiatives with large clinical organizations.

Macro / Industry Outlook:

• Regulatory Environment: Leveraging FDA Project Orbis for harmonized global approvals; utilizing Project Frontrunner to move immunotherapy earlier in the treatment sequence; targeting accelerated approval pathways based on ORR and duration of response metrics.
• Global Epidemiology: Addressing esophageal cancer as the sixth leading cause of cancer death globally, with significant incidence in Asian markets driving ex-U.S. partnership interest.
• Tax/Legal: No specific tax rate guidance provided; managing potential audit adjustments on Udenica divestiture milestones.

Strategic Initiatives:

• Asset Prioritization: Executing a "right-sizing" strategy by deprioritizing non-esophageal TAGMO-Keto indications to concentrate resources.
• M&A/Partnership: Engaging financial advisors to conduct ex-U.S. partnering for TAGMO-Keto; seeking upfront payments to offset clinical costs and partner-funded registration trials.
• Operational Restructuring: Completing process transfer of Toripalimab from China to the U.S. (approved Nov 30, 2026); winding down transition services agreement (TSA) with Udenica acquirer; reducing headcount by 30% in Q3 2026.
• Clinical Trials: Launching randomized Phase 2 study for TAGMO-Keto + Toripalimab in second-line esophageal cancer; continuing maturation of Kesdoza-Keto cohort.

Risks and Headwinds to Outlook:

• Execution Risk: Success of revenue targets ($25–30M/quarter) depends on overcoming patient flow lumps and physician habit inertia in switching to Loctrosis.
• Clinical Risk: Dependence on positive outcomes in the second-line randomized study for accelerated approval; potential safety issues with cisplatin-based combinations (plan to switch to oxaliplatin).
• Financial Risk: Current cash runway <12 months; reliance on successful ex-U.S. partnering, milestone payments, or additional financing to avoid dilution.
• Regulatory Risk: FDA acceptance of accelerated approval endpoints (ORR/duration) and combination of histologies (SCC/EAC) in the second-line setting.
• Audit Risk: Uncertainty surrounding final adjustments to the Udenica earn-out threshold.

Management Tone on the Future:

• Confidence: Management expresses high confidence in the "best-in-disease" potential of TAGMO-Keto in esophageal cancer, citing clear dose-dependent activity and unmet medical need.
• Hedges: Reiterates standard forward-looking statement disclaimers regarding clinical data maturation and market adoption rates.
• Strategic Shift: Tone indicates a decisive pivot from a "broad development" approach to a "focused, financially self-sustaining" model, acknowledging past burn inefficiencies (TSA, broad cohorts) are now being corrected.

Miscellaneous:

• Timeline: FDA meetings to finalize dose and study design scheduled for Q1 2027; data readouts for second-line study and Kesdoza maturation expected throughout 2027.
• Headcount: Reduction from ~140 to ~100 FTEs immediately, preserving the commercial organization to drive Loctrosis sales.
• Events: Management to participate in Guggenheim and Jeffries London conferences following the call.